Protein biomarker signature in patients with spinal and bulbar muscular atrophy
Authors:
- Spencer B. HuggettSHSpencer B. Huggett
- Vittoria LombardiVLVittoria Lombardi
- Luca ZampedriLZLuca Zampedri
- Abdullah AlQahtaniAAAbdullah AlQahtani
- Angela KokkinisAKAngela Kokkinis
- Andrea MalaspinaAMAndrea Malaspina
- Carlo RinaldiCRCarlo Rinaldi
- Christopher GrunseichCGChristopher Grunseich
- Pietro FrattaPFPietro Fratta
- Vissia VigliettaVVVissia Viglietta
Open Access
- 23 May 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (13)
Abstract
Spinal and bulbar muscular atrophy (SBMA) is a slowly progressing disease with limited sensitive biomarkers that support clinical research. We analyzed plasma and serum samples from patients with SBMA and matched healthy controls in multiple cohorts, identifying 40 highly reproducible SBMA-associated proteins out of nearly 3,000 measured. These proteins were robustly enriched in gene sets of skeletal muscle expression and processes related to mitochondria and calcium signaling. Many proteins outperformed currently used clinical laboratory tests (e.g., creatine kinase [CK]) in distinguishing patients from controls and in their correlations with clinical and functional traits in patients. Two of the 40 proteins, Ectodysplasin A2 receptor (EDA2R) and Repulsive guidance molecule A (RGMA), were found to be associated with decreased survival and body weight in a mouse model of SBMA. In summary, we identified what we believe to be a robust and novel set of fluid protein biomarkers in SBMA that are linked with relevant disease features in patients and in a mouse model of disease. Changes in these SBMA-associated proteins could be used as an early predictor of treatment effects in clinical trials.Keywords
This publication has 55 references indexed in Scilit:
- Troponin T in spinal and bulbar muscular atrophy (SBMA)Journal of the Neurological Sciences, 2023
- Plasma proteome profiling using tandem mass tag labeling technology reveals potential biomarkers for Parkinson's disease: a preliminary studyProteomics – Clinical Applications, 2021
- Myofiber androgen receptor increases muscle strength mediated by a skeletal muscle splicing variant of Mylk4iScience, 2021
- RGMa can induce skeletal muscle cell hyperplasia via association with neogenin signalling pathwayIn Vitro Cellular & Developmental Biology - Animal, 2021
- MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and EfficacyAnnals of Neurology, 2020
- Molecular Mechanisms and Therapeutics for SBMA/Kennedy's DiseaseNeurotherapeutics, 2019
- Biofluid Biomarkers in Huntington’s Disease2018
- Mass spectrometry‐based protein analysis to unravel the tissue pathophysiology in Duchenne muscular dystrophyProteomics – Clinical Applications, 2017
- Identification of KLHL41 Mutations Implicates BTB-Kelch-Mediated Ubiquitination as an Alternate Pathway to Myofibrillar Disruption in Nemaline MyopathyThe American Journal of Human Genetics, 2013
- Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophyJournal of Neurology, 2011